Mounting capital demands in AI and space are making indefinite private ownership increasingly impractical for mega-scale tech firms. Companies like Anthropic, OpenAI, and SpaceX face structural ...
On December 30, Chinese AI company Z.ai launched a share sale to raise HK$4.35 billion (approx. US$560 million), aiming to become the first large language model (LLM) developer listed in Hong Kong ...
HashKey opens IPO subscriptions as it seeks to raise $214.7 million, valuing Hong Kong’s biggest crypto exchange at about $2.5 billion. HashKey Group, operator of one of Hong Kong’s licensed crypto ...
HashKey Holdings Ltd., operator of Hong Kong’s largest licensed crypto exchange, is seeking to raise as much as HK$1.67 billion ($215 million) through an initial public offering. The company is ...
CMS is developing the ACCESS Model, a new national program that will pay Medicare Part B–enrolled organizations based on chronic-condition outcomes, care coordination and social-needs integration, ...
Nov 19 (Reuters) - Kraken, one of the world's largest cryptocurrency exchanges, said on Wednesday it has confidentially filed for an initial public offering in the U.S., as digital asset companies ...
Grayscale Investments, the company behind the Bitcoin Trust ETF (GBTC) and CoinDesk Crypto 5 ETF (GDLC) among other exchange traded funds, filed to sell shares on the New York Stock exchange, joining ...
Hosted on MSN
SEBI Chief Highlights Strength of India’s BRSR Framework, Rules Out Interference in IPO Pricing
Mumbai (Maharashtra), Nov 06 2025 (ANI): SEBI Chief Tuhin Kanta Pandey says, "They are not one-size-fits-all standards. In fact, India's BRSR (Business Responsibility & Sustainability Reporting) ...
The Vermont-based company’s shares were priced at $34 for its initial public offering (IPO), exceeding the projected range of $27 to $33. Beta Technologies sold 29.9 million shares, raising over $1 ...
LAS VEGAS—Hinge Health and Omada Health were the first two digital health companies to go public this year after an IPO drought, and the industry has been counting on them to open the floodgates. The ...
Less than two years after laying out plans to divest its China operations and become a U.S.-focused biotech, I-Mab Biopharma is re-staking its claim in the Asia-Pacific region. The drugmaker mapped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results